Breast Cancer Clinical Trial
Official title:
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help
doctors learn more about differences in DNA and predict how well patients will respond to
treatment and plan better treatment.
PURPOSE: This clinical trial is studying blood samples from women with breast cancer or
ductal carcinoma in situ who are receiving tamoxifen.
OBJECTIVES:
Primary
- To evaluate the change in endoxifen levels after an increase in tamoxifen citrate dose
from 20 mg to 40 mg in women with breast cancer or ductal breast carcinoma in situ with
intermediate-metabolizing CYP2D6 genotypes.
Secondary
- To evaluate the tolerability of increasing the dose of tamoxifen citrate from 20 to 40
mg per day in these patients.
- To assess the feasibility of obtaining pharmacogenomic information from patients in the
clinical setting and using it to guide changes in therapy.
- To examine CYP2D6 allele frequencies and endoxifen levels among African-American women
taking tamoxifen citrate.
- To evaluate the change in plasma endoxifen levels after an increase in the tamoxifen
citrate dose from 20 mg to 40 mg daily in patients with poor-metabolizing genotypes.
- To study patient understanding of pharmacogenomics and obstacles to participation in
clinical trials based upon germline DNA.
OUTLINE: This is a multicenter study.
Blood samples are collected at baseline to determine CYP2D6 genotype and tamoxifen citrate
metabolic status (i.e., poor-metabolizing [PM], intermediate-metabolizing [IM], or
extensive-metabolizing [EM] alleles). Samples are also analyzed for plasma levels of
endoxifen and N-desmethyltamoxifen and for endoxifen/N-desmethyltamoxifen ratio. Patients
found to be IM or PM are notified to increased tamoxifen citrate to 40 mg/day for 4 months
(in the absence of unacceptable toxicity) with repeat endoxifen and N-desmethyltamoxifen
levels (and the ratio) at the end of this time.
All patients complete Quality Of Life (QOL) and Menopausal Symptoms Scale (MSS)
questionnaires at baseline and after 4 months of treatment. Toxicities are assessed at the
end of 4 months. Patients undergo repeat questionnaire assessment of their understanding of
the use of pharmacogenomics in clinical decision-making. Some patients also undergo a
30-minute, baseline interview regarding attitudes and experience towards participation in a
pharmacogenomics study.
Patients who choose to be informed of the results of their genotyping are contacted by
letter, along with their physicians, and offered genetic counseling to discuss the
significance of these results.
After completion of study therapy, patients are followed at 3-6 months, including toxicity
assessment and QOL and MSS questionnaires.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |